This website is fully funded and supported by Gilead Sciences Europe Ltd

We are committed to developing innovative therapies for life-threatening diseases

Building on our heritage in antiviral care,​ ​we are using our expertise to support the fight against COVID-19

 

Since December 2019, COVID-19 has drastically changed the world in which we live.

At Gilead, we have always done our utmost to help protect the global population from life-threatening illnesses. ​COVID-19 is no exception: we remain dedicated to developing innovative therapies to help fight the COVID-19 pandemic.

If you are a member of the public and would like to access the patient information on remdesivir please click here.

REFERENCES AND FOOTNOTES

COVID-19, coronavirus disease 2019.

This website has been designed, built and funded by Gilead. Any information or decision with regards to treatment with Gilead medicines should be discussed with your healthcare professional.

If you experience a side effect please report this information to Gilead by email to Safety_FC@Gilead.com or call +44 (0) 1223 897500.
For the UK, side effects may be reported via the dedicated COVID-19 Yellow Card reporting site at https://coronavirus-yellowcard.mhra.gov.uk.
For Ireland, reporting forms and information can be found at www.hpra.ie. Events can also be reported to HPRA on +353 16764971.